Cover Image

A physiologically based pharmacokinetic model of ketoconazole and its metabolites as drug-drug interaction perpetrators

The antifungal ketoconazole, which is mainly used for dermal infections and treatment of Cushing’s syndrome, is prone to drug-food interactions (DFIs) and is well known for its strong drug-drug interaction (DDI) potential. Some of ketoconazole’s potent inhibitory activity can be attributed to its me...

Full description

Saved in:
Bibliographic Details
Main Authors: Marok, Fatima (Author) , Wojtyniak, Jan-Georg (Author) , Fuhr, Laura Maria (Author) , Selzer, Dominik (Author) , Schwab, Matthias (Author) , Weiß, Johanna (Author) , Haefeli, Walter E. (Author) , Lehr, Thorsten (Author)
Format: Article (Journal)
Language:English
Published: 17 February 2023
In: Pharmaceutics
Year: 2023, Volume: 15, Issue: 2, Pages: 1-22
ISSN:1999-4923
DOI:10.3390/pharmaceutics15020679
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.3390/pharmaceutics15020679
Verlag, lizenzpflichtig, Volltext: https://www.mdpi.com/1999-4923/15/2/679
Get full text
Author Notes:Fatima Zahra Marok, Jan-Georg Wojtyniak, Laura Maria Fuhr, Dominik Selzer, Matthias Schwab, Johanna Weiss, Walter Emil Haefel and Thorsten Lehr
Description
Summary:The antifungal ketoconazole, which is mainly used for dermal infections and treatment of Cushing’s syndrome, is prone to drug-food interactions (DFIs) and is well known for its strong drug-drug interaction (DDI) potential. Some of ketoconazole’s potent inhibitory activity can be attributed to its metabolites that predominantly accumulate in the liver. This work aimed to develop a whole-body physiologically based pharmacokinetic (PBPK) model of ketoconazole and its metabolites for fasted and fed states and to investigate the impact of ketoconazole’s metabolites on its DDI potential. ...
Item Description:Gesehen am 05.12.2023
Physical Description:Online Resource
ISSN:1999-4923
DOI:10.3390/pharmaceutics15020679

Similar Items